Tech Company Financing Transactions
Passkey Therapeutics Funding Round
On 10/22/2024, Passkey Therapeutics secured $20 million in Seed funding from Breakout Ventures, Alexandria Venture Investments and Bison Ventures.
Transaction Overview
Company Name
Announced On
10/22/2024
Transaction Type
Venture Equity
Amount
$20,000,000
Round
Seed
Investors
Proceeds Purpose
The company intends to use the funds to support its development of SMThs (pronounced "smiths"), a new class of single-drug therapies designed to modulate rare combinations of proteins that work together, and Locksmith, its proprietary computational and experimental platform for SMTh discovery.
Company Information
Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
One Kendall Square, Building 200 001
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Undisclosed
Website
Email Address
Overview
We are biotech and pharma veterans with diverse backgrounds in computational and experimental drug discovery and a shared dedication to improving the lives of patients with complex diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Bruce Beutel
Chief Operating Officer
Peter Dandliker
Chief Technical Officer
Will Chen
Co-Founder
Soumya Ray
Vice President
Robert Gentles
VP - Finance
Joel Yeshman
Browse more venture capital transactions:
Prev: 10/22/2024: Universal Fuel Technologies venture capital transaction
Next: 10/22/2024: Vortexa venture capital transaction
Share this article
News on VC Transactions
We report on all VC transactions involving tech companies. All VC database entries reported here come from a variety of public sources. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs